Showing results (601-610 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|June 15, 2021
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United StatesMatthew Stargardter, Ali McBride, Jon Tosh, et al.Journal of Medical Economics|December 18, 2020
A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancerJoshua A Roth, Yong Yuan, Megan Othus, et al.Journal of Medical Economics|June 21, 2022
Hospitalization costs of adult community-acquired pneumonia in EnglandJames Campling, Hannah F Wright, Gillian C Hall, et al.Journal of Medical Economics|December 15, 2022
Estimation of the utilities of attributes of intravenous iron infusion treatment for patients with iron-deficiency anemia: a conjoint analysis in JapanTomomi Takeshima, Chise Ha, Kosuke IwasakiJournal of Medical Economics|December 22, 2022
To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosisStephen Maxwell Montgomery, Luke Green, Hajer Karoui, et al.Journal of Medical Economics|June 15, 2022
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in SpainAndrés Muñoz, Enrique Gallardo, Giancarlo Agnelli, et al.Journal of Medical Economics|June 1, 2022
Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel studyErik Landfeldt, Rongrong Zhang, Anne-Marie Childs, et al.Journal of Medical Economics|June 8, 2022
Budget impact analysis of belumosudil for chronic graft-versus-host disease treatment in the United StatesCarlos R Bachier, Jeffrey R Skaar, Sumudu Dehipawala, et al.Journal of Medical Economics|June 22, 2022
The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystoniaNatalya Danchenko, Karissa M Johnston, John WhalenJournal of Medical Economics|December 1, 2022
Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database studyLisa M Hess, Diane Michael, Peter M Krein, et al.Pageof 241